Haverford Trust Company’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.9M Buy
387,129
+84,941
+28% +$2.26M 0.1% 98
2025
Q4
$7.52M Sell
302,188
-80,386
-21% -$2.03M 0.07% 108
2025
Q3
$9.75M Sell
382,574
-28,547
-7% -$705K 0.09% 103
2025
Q2
$9.97M Sell
411,121
-29,754
-7% -$694K 0.09% 101
2025
Q1
$11.2M Buy
440,875
+80,495
+22% +$2.11M 0.11% 95
2024
Q4
$9.56M Sell
360,380
-131,837
-27% -$3.58M 0.09% 100
2024
Q3
$14.2M Sell
492,217
-12,901
-3% -$376K 0.14% 89
2024
Q2
$14.1M Buy
505,118
+842
+0.2% +$23.2K 0.15% 88
2024
Q1
$14M Sell
504,276
-12,453
-2% -$346K 0.15% 88
2023
Q4
$14.9M Buy
516,729
+14,003
+3% +$423K 0.17% 81
2023
Q3
$16.7M Sell
502,726
-19,933
-4% -$705K 0.2% 71
2023
Q2
$19.2M Sell
522,659
-13,643
-3% -$531K 0.22% 71
2023
Q1
$21.9M Buy
536,302
+3,830
+0.7% +$165K 0.26% 66
2022
Q4
$27.3M Buy
532,472
+207
+0% +$9.92K 0.34% 61
2022
Q3
$23.3M Buy
532,265
+10,977
+2% +$533K 0.32% 60
2022
Q2
$27.3M Sell
521,288
-40,685
-7% -$2.07M 0.36% 60
2022
Q1
$29.1M Buy
561,973
+17,922
+3% +$930K 0.34% 63
2021
Q4
$32.1M Sell
544,051
-659
-0.1% -$32.7K 0.35% 60
2021
Q3
$23.4M Buy
544,710
+6,167
+1% +$273K 0.28% 64
2021
Q2
$21.1M Buy
538,543
+60,714
+13% +$2.36M 0.25% 66
2021
Q1
$17.3M Buy
477,829
+4,246
+0.9% +$151K 0.22% 67
2020
Q4
$17.4M Sell
473,583
-21,193
-4% -$777K 0.25% 59
2020
Q3
$17.2M Buy
494,776
+76
+0% +$2.67K 0.27% 59
2020
Q2
$15.3M Sell
494,700
-11,404
-2% -$387K 0.26% 60
2020
Q1
$15.7M Buy
506,104
+31,659
+7% +$1.08M 0.32% 59
2019
Q4
$17.6M Buy
474,445
+906
+0.2% +$32.3K 0.29% 65
2019
Q3
$16.1M Sell
473,539
-9,463
-2% -$344K 0.28% 67
2019
Q2
$19.9M Buy
483,002
+3,291
+0.7% +$131K 0.36% 62
2019
Q1
$19.3M Sell
479,711
-9,721
-2% -$389K 0.36% 63
2018
Q4
$20.3M Sell
489,432
-20,010
-4% -$831K 0.43% 57
2018
Q3
$21.3M Sell
509,442
-6,012
-1% -$231K 0.39% 60
2018
Q2
$17.7M Sell
515,454
-244,904
-32% -$8.37M 0.35% 64
2018
Q1
$25.6M Sell
760,358
-369,156
-33% -$12.7M 0.51% 54
2017
Q4
$38.8M Sell
1,129,514
-4,964
-0.4% -$169K 0.76% 45
2017
Q3
$38.4M Buy
1,134,478
+28,332
+3% +$911K 0.8% 43
2017
Q2
$35.3M Buy
1,106,146
+35,937
+3% +$1.13M 0.77% 47
2017
Q1
$34.7M Buy
1,070,209
+47,836
+5% +$1.51M 0.79% 46
2016
Q4
$31.5M Buy
1,022,373
+10,805
+1% +$330K 0.76% 47
2016
Q3
$32.5M Buy
1,011,568
+23,267
+2% +$778K 0.81% 46
2016
Q2
$33M Buy
988,301
+32,737
+3% +$1.04M 0.83% 48
2016
Q1
$26.9M Buy
955,564
+702,638
+278% +$20.1M 0.7% 52
2015
Q4
$7.75M Buy
252,926
+8,506
+3% +$268K 0.21% 66
2015
Q3
$7.28M Buy
244,420
+26,265
+12% +$842K 0.21% 61
2015
Q2
$6.94M Buy
218,155
+11,447
+6% +$373K 0.19% 64
2015
Q1
$6.82M Buy
206,708
+3,477
+2% +$111K 0.19% 68
2014
Q4
$6.01M Sell
203,231
-612
-0.3% -$17.5K 0.17% 73
2014
Q3
$5.72M Sell
203,843
-14,459
-7% -$406K 0.17% 72
2014
Q2
$6.15M Buy
218,302
+166
+0.1% +$4.73K 0.18% 71
2014
Q1
$6.65M Sell
218,136
-130,500
-37% -$3.89M 0.21% 68
2013
Q4
$10.1M Buy
348,636
+20,513
+6% +$597K 0.28% 65
2013
Q3
$8.94M Sell
328,123
-917
-0.3% -$24.9K 0.33% 53
2013
Q2
$8.74M Buy
+329,040
New +$9.09M 0.29% 64

Other funds holding PFE

Haverford Trust Company's PFE Position: Q1 2026 in Review

Haverford Trust Company increased its Pfizer (PFE) stake by 28% in Q1 2026, buying an estimated $2.26M and bringing the position to 387,129 shares worth $10.9M. The position accounts for 0.1% of the portfolio, ranked #98.

Haverford Trust Company first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $38.8M in Q4 2017. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Haverford Trust Company held 387,129 shares of Pfizer worth $10.9M as of Q1 2026.
  • Haverford Trust Company bought 84,941 Pfizer shares in Q1 2026, an estimated $2.26M.
  • Pfizer made up 0.1% of Haverford Trust Company's portfolio in Q1 2026, its #98 holding.
  • Haverford Trust Company first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Haverford Trust Company's Pfizer position peaked at $38.8M in Q4 2017.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Haverford Trust Company's 13F filing for Q1 2026, filed 11 May 2026.